-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical has been recognized as a provincial demonstration enterprise for technological innovation.
Category:
Time：2023-01-07
On January 6, the Hebei Provincial Department of Industry and Information Technology released the list of provincial-level demonstration enterprises for technological innovation for 2022. Among them, 36 companies—including Hebei Guangxiang Pharmaceutical Co., Ltd.—were recognized by the Provincial Department of Industry and Information Technology as provincial-level demonstration enterprises for technological innovation in 2022.
On January 6, the Hebei Provincial Department of Industry and Information Technology released the list of provincial-level demonstration enterprises for technological innovation for 2022. Among them, 36 companies—including Hebei Guangxiang Pharmaceutical Co., Ltd.—were recognized by the Provincial Department of Industry and Information Technology as provincial-level demonstration enterprises for technological innovation in 2022.
It is reported that the selection of demonstration enterprises for technological innovation in Hebei Province primarily evaluates enterprises from multiple aspects, including innovation investment, talent incentives, innovation collaboration, development of innovation teams, establishment of innovation infrastructure, accumulation and reserves of technological expertise, outputs of technological innovation, and benefits derived from technological innovation. The certification process is conducted in accordance with requirements set forth in documents such as the "Administrative Measures for the Certification of Demonstration Enterprises for Technological Innovation in Hebei Province," and involves procedures including initial review and recommendation by the industrial and information technology bureaus of various cities, preliminary document review, expert evaluation, on-site inspections, and public online announcement.
Guangxiang Pharmaceutical serves as the origin for Shijiazhuang Fourth Pharmaceutical Group’s strategy of building an integrated “API + Formulation” business model, accelerating industrial transformation, and strengthening and extending the supply chain. Since last year, Guangxiang Pharmaceutical has continuously refined its innovation mechanisms, stepped up efforts to build a robust science and technology innovation system, and significantly increased investment in research and development capabilities. The company has been relentlessly tackling key core technologies—such as independent R&D of specialty APIs and high-end APIs, as well as API synthesis—while speeding up the pace of research projects and the commercialization of their results, thereby enhancing the resilience of its innovation, industrial, and supply chains. Meanwhile, leveraging research approaches like “listing challenges and appointing leaders” and “flexible recruitment of expert talent,” Guangxiang Pharmaceutical has successively established collaborations with prestigious research institutions including Tsinghua University and Tianjin University. These partnerships have helped forge an independent innovation system centered on industry-academia-research-application integration, technological platform development, and new product R&D, thus creating a new engine of momentum for the company’s innovative growth.
In 2022, Guangxiang Pharmaceutical successfully achieved the commercialization of eight distinctive active pharmaceutical ingredients (APIs), including pentoxifylline, levonidazole, and ornidazole. These technological innovations have provided strong support for the company’s high-quality development. Guided by innovation-driven strategies, Guangxiang Pharmaceutical has successively been recognized as a High-Tech Enterprise, a Provincial Enterprise Technology Center, a Provincial Technology Innovation Center, a Provincial Engineering Research Center for Continuous Synthesis of APIs via Micro-Reactions, a Postdoctoral Research Workstation, a Provincial Science and Technology-based SME, a Provincial Specialized, Refined, and Novel Demonstration Enterprise, a Provincial Industrial Enterprise R&D Institution (Grade A), and a Provincial Green Factory.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license